Robin Whitaker
Family Medicine · Hazard, KYNPI 1477560605
Payments from drug & device makers
Across 82 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$394
- Astellas Pharma US Inc$248
- Gilead$192
- Novo Nordisk$60
- Lilly USA, LLC$53
- Takeda Pharmaceuticals U.S.A., Inc.$48
- plus $391 from 20 others
What the payments were for
- Food & beverage$1,14683%
- Education$24017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 32 | $394 |
| Astellas Pharma US Inc | 4 | $248 |
| Gilead | 8 | $192 |
| Novo Nordisk | 4 | $60 |
| Lilly USA, LLC | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $48 |
| Daiichi Sankyo Inc. | 3 | $45 |
| Amgen(2 entities) | 2 | $29 |
| Organon | 2 | $27 |
| AbbVie(2 entities) | 2 | $26 |
| AstraZeneca | 2 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Exeltis, USA Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Myovant Sciences Inc. | 1 | $12 |
| Esperion Therapeutics, Inc. | 1 | $11 |
How this compares
$1,386 in reported general payments places this provider in the 60th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 11 | $9,406 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 48 | $1,037 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $905 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $600 |
| Amitriptyline Hcl | 20 | $518 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $374 |
| Levothyroxine Sodium | 40 | $320 |
| Pregabalin | 15 | $237 |
| Atorvastatin Calcium | 27 | $203 |
| Sertraline Hcl | 13 | $42 |
| Metoprolol Tartrate | 12 | $19 |
| Lisinopril | 15 | $18 |
| Hydrochlorothiazide | 14 | $11 |
| Gabapentin | 12 | $6 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $16 | $9,40611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Hazard
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.